|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||307.386 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion. The ocular efficacy of moxaverine has been explored in the clinic.
- Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittelforschung. 38 (12): 1806–8. PMID 2854468.
- Schmid-Schönbein, H; Schröder, S; Grebe, R; Artmann, G; Eschweiler, H; Teitel, P (1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittelforschung. 38: 710–716. PMID 3415714.
- Pemp, B; Garhofer, G; Lasta, M; Schmidl, D; Wolzt, M; Schmetterer, L (2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmol. 90: 139–145. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253.
- "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects".
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|